Vaxxel, a spin off from VirPath laboratory (INSERM, CNRS, Université Claude Bernard Lyon1 in Lyon, France), has been founded in September 2019. Vaxxel develops innovative and proprietary live-attenuated vaccine candidates against bronchiolitis and pneumonia caused by pneumoviruses. The objective of Vaxxel’s technology aims to mimic natural infection by activating both humoral and mucosal immunity without causing the disease. Monovalent and bivalent live-attenuated viral vaccine candidates are based on the Vaxxel’s proprietary Metavac® vaccine platform which has already demonstrated protective property against Human Metapneumovirus infection in pre-clinical models. In parallel, Vaxxel is developing a full production and purification pilot process based the patented avian DuckCelt®-T17 cell line adapted to large-scale serum-free production in bioreactors. Vaxxel was laureate of the i-Lab 2019 award from the French Ministry of Higher Education, Research and Innovation, and BpiFrance.